Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 0.0-21.0,  Hemophilia A Part A Moderately severe (≤2% FVIII) hemophilia A <3 Years of age at the time of informed consent Caregiver (parent or legal guardian) has provided written informed consent ≤2 EDs to pdFVIII, rFVIII, or a single dose of FFP, Cryoprecipitate or PRBCs Adequate hematologic function (HgB >8 g/dL and platelet count >100,000 µL) Adequate hepatic function (total bilirubin ≤1.5x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's) Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min) Negative test for inhibitor (<0.6 BU/mL) with a 72-hour washout within 4 weeks of enrollment No documented FVIII inhibitor since birth *Participants will be encouraged to co-enroll in the ATHN 8 Study  Part A and B Inherited or acquired bleeding disorder other than severe hemophilia A (participants with previous documentation of low von Willebrand factor (vWF) defined as vWF antigen and vWF ristocetin cofactor both between 40-50 will be permitted) Previous or current treatment for thromboembolic disease or signs of thromboembolic disease Conditions that may increase risk of bleeding or thrombosis. Will not require or request a thrombophilia evaluation History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the injection (with the exception of rituximab) Known HIV infection with CD4 count <200 cells/µL within 24 weeks prior to screening. Testing not required if can demonstrate negative testing in mother prior to pregnancy Use of systemic immunomodulators at enrollment or planned use during the study Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study Planned surgery (excluding minor procedures or central line placement) during the study